Novartis Earnings Slip 4% on Strong Dollar, Gilenya Competition

22
1
Favorite

Novartis Earnings Slip 4% on Strong Dollar, Gilenya Competition

Reuters2022-10-25

Quarterly operating income at Swiss drugmaker Novartis slipped as competition weighed on prescriptions of multiple sclerosis drug Gilenya.For Novartis, which reports results in dollars, a strong U.S. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

MrHuattt
·2022-10-25
Okay
Reply
1
Report
Fold Replies
- MrHuattt:
  Sure
  2022-10-25
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1111729530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-10-25 13:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111729530","market":"us","top_or_hot":-1,"title":"Novartis Earnings Slip 4% on Strong Dollar, Gilenya Competition","media":"Reuters","content":"<div>\n<p>Quarterly operating income at Swiss drugmaker Novartis slipped as competition weighed on prescriptions of multiple sclerosis drug Gilenya.For Novartis, which reports results in dollars, a strong U.S. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novartis-earnings-slip-4-strong-051142705.html\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Earnings Slip 4% on Strong Dollar, Gilenya Competition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Earnings Slip 4% on Strong Dollar, Gilenya Competition\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-25 13:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novartis-earnings-slip-4-strong-051142705.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quarterly operating income at Swiss drugmaker Novartis slipped as competition weighed on prescriptions of multiple sclerosis drug Gilenya.For Novartis, which reports results in dollars, a strong U.S. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novartis-earnings-slip-4-strong-051142705.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/novartis-earnings-slip-4-strong-051142705.html","article_id":"1111729530","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111729530","pubTimestamp":1666676025,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Quarterly operating income at Swiss drugmaker Novartis slipped as competition weighed on prescriptio","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"美元强劲，吉伦亚竞争，诺华收益下滑4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"Quarterly operating income at Swiss drugmaker Novartis slipped as competition weighed on prescriptions of multiple sclerosis drug Gilenya.For Novartis, which reports results in dollars, a strong U.S. currency was also a drag on the value of sales generated outside the United States.Third-quarter core operating income declined 4% to $4.28 billion, slightly below the average analyst consensus of $4.30 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9988345902,"gmtCreate":1666676151506,"gmtModify":1676537788277,"author":{"id":"4089116574465250","authorId":"4089116574465250","name":"MrHuattt","avatar":"https://community-static.tradeup.com/news/e67f8f8c2b0192fadc4cd499a84e6c8b","vip":1,"crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"4089116574465250","idStr":"4089116574465250"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9988345902","repostId":1111729530,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104500988,"gmtCreate":1666676155253,"gmtModify":1666676159168,"authorId":4089116574465250,"author":{"id":4089116574465250,"idStr":"4089116574465250","authorId":4089116574465250,"name":"MrHuattt","avatar":"https://community-static.tradeup.com/news/e67f8f8c2b0192fadc4cd499a84e6c8b","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9988345902,"type":1,"supId":0,"prevId":0,"content":"<u>Sure</u>","text":"<u>Sure</u>","html":"<u>Sure</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":22,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}